In this review, we listed the drug information of developed BCL-2 inhibitors (Table 1 and Figure 1), elaborated the mechanism of BCL-2 inhibition, briefly described the achieved progress of venetoclax in hematological malignancies, and discussed the indicative genetic mutations that influence the therapeutic effects. The gene discussed is BCL2; the disease is hematologic disorder.